Skip to content

Multidimensional Clinical Evaluation and Analgesic Mechanism Study of Topical Regulation of "Central-Peripheral" Electroencephalographic Pain Sensitization by Shujin Huoxue Chinese Medicine Patch to Improve Chronic Pain in Early-Mid Stage Knee Osteoarthritis

Multidimensional Clinical Evaluation and Analgesic Mechanism Study of Topical Regulation of "Central-Peripheral" Electroencephalographic Pain Sensitization by Shujin Huoxue Chinese Medicine Patch to Improve Chronic Pain in Early-Mid Stage Knee Osteoarthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000927
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-03
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Control Group:Basic treatment plus oral Glucosamine hydrochloride capsules
Positive control group:Basic treatment + Compound Nanxing Pain-relieving Plaster
Treatment group:Basic treatment + Chinese herbal medicine patch for muscle relief and blood circulation

Sponsors

Guangdong Second Provincial Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged 55 to 80 years with unilateral knee osteoarthritis undergoing conservative treatment; meeting the diagnostic criteria of the "Guidelines for Integrated Traditional and Western Medicine Diagnosis and Treatment of Knee Osteoarthritis (2023 Edition)"; Kellgren-Lawrence grading of I to II; no mental abnormalities, able to communicate accurately; no systematic use of nonsteroidal anti-inflammatory drugs, glucocorticoids, or intra-articular injection agents in the past month; body mass index of 18.5 to 28 kg/m²; willing to participate in the trial with good compliance, and agree to join this research study.

Exclusion criteria

Exclusion criteria: Patients who do not meet the inclusion criteria; non-primary knee osteoarthritis, such as gouty arthritis, hemophilic arthritis, etc.; severe varus or valgus deformities of the knee joint (deformity angle >15°) with (or without) ankylosis (knee joint range of motion <90°), or accompanied by severe bone defects; patients with significant systemic functional disorders or severe chronic cardiovascular diseases; patients with skin abrasions, ulcers, or local infections who are unsuitable for topical ointment application; patients who have undergone knee surgery in the past six months; patients with other diseases accompanied by lower extremity pain, such as lumbar disc herniation or lumbar spinal stenosis; individuals engaged in professional sports or physically demanding occupations; patients with a history of lower extremity vascular lesions.

Design outcomes

Primary

MeasureTime frame
Brain Electrophysiological Atlas;

Secondary

MeasureTime frame
Visual Analogue Scale Pain Score;The Western Ontario and McMaster Universities Osteoarthritis Index;Knee Swelling Degree;Serum Interleukin-1ß, Interleukin-6, Tumor Necrosis Factor-alpha, and Prostaglandin E2 detection.;Serum succinic acid metabolic level;Serum inflammation/immune protein expression;

Countries

China

Contacts

Public ContactLiu Wengang

Guangdong Second Provincial Traditional Chinese Medicine Hospital

914194079@qq.com13924037789

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026